$IQV

Patel Bhavik sold $436K of IQV

Patel Bhavik (See Remarks) sold 1,855 shares of IQVIA HOLDINGS INC. (IQV) at $235.27 ($0.44M total) on 2026-07-31.

Original reporting
SEC EDGAR · Patel Bhavik
Published Aug 4, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IQV
Neutral
medium confidence
Mentioned
$IQV
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IQVNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not introduce new operational, financial, or regulatory information about IQVIA.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no direct fundamental catalyst in the text.

03

What to watch

Insider sales are often driven by taxes, diversification, or pre-existing compensation schedules; without stated purpose, the signal quality is low.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-04 after-hours; sale dated 2026-07-31

Background

The article is a SEC Form 4 insider transaction disclosure for IQVIA Holdings Inc.

Company-level read

Ticker impact

$IQVNeutralMedium confidence
Context

IQVIA Form 4 shows officer Patel Bhavik sold 1,855 shares on 2026-07-31 at $235.27 for about $436.4K.

Expected impact

Likely limited near-term impact; any effect would be brief and sentiment-driven rather than a fundamental repricing.

Evidence & confidence

The filing discloses transaction size and price but provides no new company performance, guidance, or regulatory/legal catalyst. Insider sales can be non-informational, and the article lacks additional context (e.g., compensation, tax, diversification).

Market effects

Minimal; insider-sale disclosures rarely change sector fundamentals for healthcare services/pharma services.

None indicated.

None indicated.

Counterpoint

Absence of a 10b5-1 plan could be interpreted by some traders as potentially more informative than typical planned sales, even though the article provides no rationale.

Key entities

  • IQVIA HOLDINGS INC.

    Subject of the Form 4 insider transaction disclosure.

  • Patel Bhavik

    Officer who sold 1,855 shares in an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IQVHighAI 9/10

Will IQVIA’s Upgraded 2026 Guidance and Bookings Strength Change IQVIA Holdings' (IQV) Narrative

IQVIA Holdings (IQV) reported Q2 earnings that beat expectations, with adjusted earnings up 12.1% and revenue up 8.7% year over year. The company raised its 2026 guidance for revenue, adjusted EBITDA, and earnings, citing strong bookings and acquisitions. Management attributes the upgrade to broad-based demand and operational efficiency, including AI-driven initiatives like IQVIA.ai. The stock is projected to reach $20.4 billion in revenue and $2.0 billion in earnings by 2029, representing a 5%

$IQVMed

How IQVIA’s Medera Cardiac Gene Therapy Alliance and Raised 2026 Outlook Will Impact IQV (IQV) Investors

IQVIA Inc. said it raised full-year 2026 revenue guidance to US$17.28–US$17.48 billion, with Q3 outlook of US$4.32–US$4.39 billion, alongside reporting Q2 results and buyback activity. IQVIA also announced a collaboration with Medera Inc. on cardiac gene therapies and human-based drug discovery, linking IQVIA trial and platform capabilities to Medera programs.

$IQVMed

5 Insightful Analyst Questions From IQVIA’s Q2 Earnings Call

IQVIA reported Q2 CY2026 results with revenue of $4.37B versus $4.30B estimates and adjusted EPS of $3.15 versus $3.03, with adjusted EBITDA of $994M. Management cited 6% organic growth and strong net new bookings. Full-year revenue guidance was lifted to $17.38B and adjusted EPS to $12.90. Analysts discussed bookings, outsourcing, AI, M&A, and margins.

Med

An IQVIA CEO Sold $26.1 Million as Bookings Hit a Record $3.15 Billion

IQVIA Holdings CEO sold about $26.1 million of stock appreciation rights with a Feb 2027 expiration, while retaining a large share position, according to the filing and article. The company reported Q2 revenue up 8.7% to $4.37B, adjusted EPS up 12.1% to $3.15, and record clinical bookings of $3.15B, raising full-year guidance to $17.475B.